Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
- Revenue in EUR (TTM)6.66bn
- Net income in EUR189.00m
- Incorporated1987
- Employees23.74k
- LocationGrifols SAC/ Jesus y Maria, 6BARCELONA 08022SpainESP
- Phone+34 935710000
- Fax+34 935710267
- Websitehttps://www.grifols.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financiere de Tubize SA | 0.00 | 183.85m | 5.19bn | -- | 28.23 | 2.75 | 28.23 | -- | 4.13 | 4.13 | 0.00 | 42.45 | 0.00 | -- | -- | -- | 9.64 | 7.04 | 9.85 | 7.24 | -- | -- | -- | 145.70 | -- | -- | 0.0161 | 20.94 | -- | -- | 3.50 | -20.93 | -- | 11.61 |
Organon & Co | 5.84bn | 964.18m | 5.26bn | 10.00k | 5.44 | 118.28 | 4.42 | 0.8991 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
Aspen Pharmacare Holdings Limited | 2.15bn | 244.76m | 5.41bn | 8.61k | 21.99 | 1.25 | 17.15 | 2.52 | 10.96 | 10.96 | 96.12 | 192.69 | 0.3286 | 1.28 | 3.33 | 4,958,198.00 | 3.75 | 3.54 | 4.42 | 4.44 | 45.15 | 48.72 | 11.40 | 11.58 | 1.09 | 6.50 | 0.2967 | 19.47 | 5.45 | 1.22 | -19.42 | -1.44 | 1.00 | 1.66 |
Orion Oyj | 1.22bn | 216.80m | 5.81bn | 3.70k | 26.65 | 8.19 | 22.00 | 4.76 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
Grifols SA | 6.66bn | 189.00m | 5.82bn | 23.74k | 32.76 | 1.05 | 8.18 | 0.8744 | 0.2813 | 0.2813 | 9.89 | 8.75 | 0.3074 | 1.18 | 7.07 | 280,331.60 | 1.31 | 2.39 | 1.68 | 3.04 | 38.63 | 40.26 | 4.27 | 7.54 | 1.02 | 1.78 | 0.5839 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 9.76bn | 521.37m | 5.85bn | 28.05k | 11.82 | 1.32 | -- | 0.5996 | 2.52 | 2.52 | 47.25 | 22.68 | 1.01 | 6.70 | 4.70 | 2,739,343.00 | 5.67 | 5.90 | 10.56 | 12.40 | 18.07 | 18.70 | 5.63 | 5.56 | 1.35 | -- | 0.3132 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
Elanco Animal Health Inc | 4.02bn | -1.20bn | 5.87bn | 9.30k | -- | 1.05 | -- | 1.46 | -2.64 | -2.64 | 8.84 | 12.26 | 0.2931 | 1.21 | 4.28 | 469,354.80 | -8.74 | -3.27 | -9.65 | -3.65 | 55.28 | 54.28 | -29.83 | -11.53 | 1.96 | 0.853 | 0.4877 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
Beijing Tiantan Biological Products Corp | 649.04m | 147.91m | 6.19bn | 4.86k | 34.88 | 4.01 | -- | 9.54 | 0.7068 | 0.7068 | 3.10 | 6.15 | 0.3611 | 0.9104 | 171.46 | 1,051,960.00 | 11.18 | 11.71 | 16.00 | 16.50 | 52.26 | 49.39 | 30.97 | 27.71 | 3.41 | -- | 0.0094 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 33.99 |
Sino Biopharmaceutical Ltd | 3.34bn | 235.24m | 6.21bn | 25.81k | 26.03 | 1.56 | 8.67 | 1.86 | 0.1076 | 0.1359 | 1.53 | 1.79 | 0.4104 | 2.31 | 5.73 | 1,096,032.00 | 7.23 | 13.11 | 13.37 | 21.74 | 80.95 | 80.37 | 17.61 | 27.47 | 0.9649 | 11.83 | 0.2479 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
Beijing Tongrentang Co Ltd | 2.28bn | 218.62m | 6.40bn | 16.78k | 29.27 | 3.71 | -- | 2.80 | 1.26 | 1.26 | 13.11 | 9.90 | 0.6079 | 1.23 | 10.82 | 1,072,010.00 | 8.84 | 8.20 | 16.50 | 16.17 | 45.32 | 46.59 | 14.55 | 13.33 | 2.28 | -- | 0.1632 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
Jazz Pharmaceuticals PLC | 3.54bn | 304.63m | 6.48bn | 2.80k | 23.02 | 1.90 | 7.19 | 1.83 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 2.00 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Holder | Shares | % Held |
---|---|---|
Capital International Ltd.as of 03 Jul 2024 | 17.16m | 4.03% |
DWS Investment GmbHas of 10 Jun 2024 | 13.78m | 3.23% |
Capital Research & Management Co. (World Investors)as of 11 Jun 2024 | 13.75m | 3.23% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 9.79m | 2.30% |
Norges Bank Investment Managementas of 31 Dec 2023 | 9.60m | 2.25% |
Hardman Johnston Global Advisors LLCas of 28 Jun 2024 | 9.59m | 2.25% |
BNP Paribas Asset Management Europe SASas of 13 Mar 2024 | 8.38m | 1.97% |
BlackRock Fund Advisorsas of 04 Jul 2024 | 7.35m | 1.73% |
Caixabank Asset Management SGIIC SAas of 31 Dec 2023 | 5.32m | 1.25% |
Rokos Capital Management LLPas of 31 Dec 2023 | 4.84m | 1.14% |